September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Influence of pilocarpine and timolol on human meibomian gland epithelial cells.
Author Affiliations & Notes
  • Yi Zhang
    Department of Ophthalmology, Schepens Eye Research Institute, Boston, Massachusetts, United States
  • Wendy Kam
    Department of Ophthalmology, Schepens Eye Research Institute, Boston, Massachusetts, United States
  • David A Sullivan
    Department of Ophthalmology, Schepens Eye Research Institute, Boston, Massachusetts, United States
  • Footnotes
    Commercial Relationships   Yi Zhang, None; Wendy Kam, None; David Sullivan, None
  • Footnotes
    Support  NIH grant EY05612 and the Margaret S. Sinon Scholar in Ocular Surface Research Fund.
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 5707. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Yi Zhang, Wendy Kam, David A Sullivan; Influence of pilocarpine and timolol on human meibomian gland epithelial cells.. Invest. Ophthalmol. Vis. Sci. 2016;57(12):5707.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Recently, investigators have discovered that topical anti-glaucoma drugs may induce meibomian gland dysfunction. This response may contribute to the decreased tear volume, tear film instability, posterior blepharitis, loss of visual acuity and symptoms of ocular burning, stinging, discomfort, redness, photophobia and foreign-body sensation commonly found in glaucoma patients taking such medications. We hypothesize that the action of these drugs may involve a direct effect on human meibomian gland epithelial cells (HMGECs). To begin to test this hypothesis, we examined the influence of the antiglaucoma drugs, pilocarpine and timlolol, on the morphology and survival of HMGECs.

Methods : Immortalized (I) HMGECs were cultured in keratinocyte serum-free media containing vehicle, pilocarpine (4.0 or 0.4%) or timolol (0.5 or 0.05%) for up to 24 hours. Experiments were repeated at least three times, and included positive controls for proliferation (epidermal growth factor and bovine pituitary extract). Cell counts were enumerated with a hemocytometer, cellular morphology was examined with a phase-contrast microscope, and statistics were performed with a one-way ANOVA.

Results : The cholinergic agonist, pilocarpine, caused a dose-dependent decrease in the survival of IHMGECs. The 4.0% concentration, which is used clinically, was toxic and led to the death of most cells. Exposure to 0.4% pilocarpine resulted in a significant decrease in the proliferation of IHMGECs, as compared to controls. A reduction in cell number was also found following treatment with 0.5% (clinical dose), but not 0.05%, timolol, a beta-adrenergic receptor antagonist. Morphologically, 4.0% pilocarpine induced cellular atrophy within 3 hours. The 0.4% pilocarpine stimulated the accumulation of perinuclear vesicles after 3 hours of exposure, and this vacuolation appeared to increase both in number and size during the experimental time course. IHMGECs treated with 0.5% timolol exhibited cell shrinkage, rounding and poor adherence by 24 hours, whereas the 0.05% dose had minimal morphological effects.

Conclusions : Our results support our hypothesis and demonstrate that these antiglaucoma drugs, pilocarpine and timolol, have direct effects on HMGECs that may influence their morphology and survival.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×